tetano
Editor, Senior Moderator
J Clin Neurosci
. 2021 Nov;93:31-35.
doi: 10.1016/j.jocn.2021.07.050. Epub 2021 Jul 28.
Residual olfactory dysfunction in coronavirus disease 2019 patients after long term recovery
Yuanyuan Zhu[SUP] 1 [/SUP], Ming Cao[SUP] 2 [/SUP], Peng Zheng[SUP] 3 [/SUP], Wei Shen[SUP] 4 [/SUP]
Affiliations
Abstract
Introduction: Hyposmia is among the most common symptoms of COVID-19 patients. Previous research has mainly described this issue at the disease's early stages. Because olfactory impairment can indicate neurological degeneration, we investigated the possibility of permanent olfactory damage by assessing hyposmia during the late recovery stage of COVID-19 patients.
Methods: Ninety-five patients were assessed with the Brief Smell Identification Test for Chinese (B-SITC) and Hyposmia Rating Scale (HRS) after 16 weeks from disease onset. Five weeks later, 41 patients were retested with B-SITC.
Results: At the first visit, hyposmia was identified in 26/82 (31.7%) and 22/95 (23.2%) of participants by HRS (HRS score ≤22) and B-SITC (B-SITC score <8), respectively. The rates of hyposmia in patients who performed B-SITC after 14-15 weeks, 16-17 weeks, and ≥18 weeks from disease onset were 7/25 (28%), 8/35 (23%) and 7/35 (20%), respectively, which demonstrated a trend of olfaction improvement as recovery time prolonging. Hyposmia percentages decreased from the first visit (34.1%) to the second visit (24.4%) for the 41 patients who completed 2 visits. B-SITC scores of the first-visit hyposmia participants increased significantly at the second visit (5.29 ± 2.02 to 8.29 ± 2.40; n = 14, P = 0.001). Severe cases tended to recover less than common cases.
Conclusions: Hyposmia was present in up to one-third of COVID-19 patients after about 3 months from disease onset. Notable recovery of olfactory function was observed at a next 5-weeks follow-up. Clinical severity had little influence on olfactory impairment and recovery.
Keywords: COVID-19; Coronavirus; Hyposmia; Neurodegenerative disease; Objective smell test.
. 2021 Nov;93:31-35.
doi: 10.1016/j.jocn.2021.07.050. Epub 2021 Jul 28.
Residual olfactory dysfunction in coronavirus disease 2019 patients after long term recovery
Yuanyuan Zhu[SUP] 1 [/SUP], Ming Cao[SUP] 2 [/SUP], Peng Zheng[SUP] 3 [/SUP], Wei Shen[SUP] 4 [/SUP]
Affiliations
- PMID: 34656257
- DOI: 10.1016/j.jocn.2021.07.050
Abstract
Introduction: Hyposmia is among the most common symptoms of COVID-19 patients. Previous research has mainly described this issue at the disease's early stages. Because olfactory impairment can indicate neurological degeneration, we investigated the possibility of permanent olfactory damage by assessing hyposmia during the late recovery stage of COVID-19 patients.
Methods: Ninety-five patients were assessed with the Brief Smell Identification Test for Chinese (B-SITC) and Hyposmia Rating Scale (HRS) after 16 weeks from disease onset. Five weeks later, 41 patients were retested with B-SITC.
Results: At the first visit, hyposmia was identified in 26/82 (31.7%) and 22/95 (23.2%) of participants by HRS (HRS score ≤22) and B-SITC (B-SITC score <8), respectively. The rates of hyposmia in patients who performed B-SITC after 14-15 weeks, 16-17 weeks, and ≥18 weeks from disease onset were 7/25 (28%), 8/35 (23%) and 7/35 (20%), respectively, which demonstrated a trend of olfaction improvement as recovery time prolonging. Hyposmia percentages decreased from the first visit (34.1%) to the second visit (24.4%) for the 41 patients who completed 2 visits. B-SITC scores of the first-visit hyposmia participants increased significantly at the second visit (5.29 ± 2.02 to 8.29 ± 2.40; n = 14, P = 0.001). Severe cases tended to recover less than common cases.
Conclusions: Hyposmia was present in up to one-third of COVID-19 patients after about 3 months from disease onset. Notable recovery of olfactory function was observed at a next 5-weeks follow-up. Clinical severity had little influence on olfactory impairment and recovery.
Keywords: COVID-19; Coronavirus; Hyposmia; Neurodegenerative disease; Objective smell test.